The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging

Mahul B. Amin, Frederick L. Greene, Stephen B. Edge, Carolyn Compton, Jeffrey E. Gershenwald, Robert K. Brookland, Laura Meyer, Donna M. Gress, David R. Byrd, David P. Winchester

Research output: Contribution to journalComment/debate

409 Citations (Scopus)

Abstract

The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a “population-based” to a more “personalized” approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as “what's new” in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93–99.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalCA Cancer Journal for Clinicians
Volume67
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Neoplasm Staging
Population
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Organizational Innovation
Benchmarking
Biological Factors
Therapeutics
Practice Guidelines

Keywords

  • American Joint Committee on Cancer (AJCC)
  • application programing interface
  • cancer stage
  • component content management system
  • electronic health record
  • precision medicine
  • prognostic factors
  • risk assessment models
  • TNM staging

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The Eighth Edition AJCC Cancer Staging Manual : Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. / Amin, Mahul B.; Greene, Frederick L.; Edge, Stephen B.; Compton, Carolyn; Gershenwald, Jeffrey E.; Brookland, Robert K.; Meyer, Laura; Gress, Donna M.; Byrd, David R.; Winchester, David P.

In: CA Cancer Journal for Clinicians, Vol. 67, No. 2, 01.03.2017, p. 93-99.

Research output: Contribution to journalComment/debate

Amin, Mahul B. ; Greene, Frederick L. ; Edge, Stephen B. ; Compton, Carolyn ; Gershenwald, Jeffrey E. ; Brookland, Robert K. ; Meyer, Laura ; Gress, Donna M. ; Byrd, David R. ; Winchester, David P. / The Eighth Edition AJCC Cancer Staging Manual : Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. In: CA Cancer Journal for Clinicians. 2017 ; Vol. 67, No. 2. pp. 93-99.
@article{1d9af841c6dd4d9b99d48bfd610c13d3,
title = "The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging",
abstract = "The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a “population-based” to a more “personalized” approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as “what's new” in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93–99.",
keywords = "American Joint Committee on Cancer (AJCC), application programing interface, cancer stage, component content management system, electronic health record, precision medicine, prognostic factors, risk assessment models, TNM staging",
author = "Amin, {Mahul B.} and Greene, {Frederick L.} and Edge, {Stephen B.} and Carolyn Compton and Gershenwald, {Jeffrey E.} and Brookland, {Robert K.} and Laura Meyer and Gress, {Donna M.} and Byrd, {David R.} and Winchester, {David P.}",
year = "2017",
month = "3",
day = "1",
doi = "10.3322/caac.21388",
language = "English (US)",
volume = "67",
pages = "93--99",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The Eighth Edition AJCC Cancer Staging Manual

T2 - Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging

AU - Amin, Mahul B.

AU - Greene, Frederick L.

AU - Edge, Stephen B.

AU - Compton, Carolyn

AU - Gershenwald, Jeffrey E.

AU - Brookland, Robert K.

AU - Meyer, Laura

AU - Gress, Donna M.

AU - Byrd, David R.

AU - Winchester, David P.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a “population-based” to a more “personalized” approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as “what's new” in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93–99.

AB - The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM-based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual, the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a “population-based” to a more “personalized” approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as “what's new” in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93–99.

KW - American Joint Committee on Cancer (AJCC)

KW - application programing interface

KW - cancer stage

KW - component content management system

KW - electronic health record

KW - precision medicine

KW - prognostic factors

KW - risk assessment models

KW - TNM staging

UR - http://www.scopus.com/inward/record.url?scp=85009446471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009446471&partnerID=8YFLogxK

U2 - 10.3322/caac.21388

DO - 10.3322/caac.21388

M3 - Comment/debate

C2 - 28094848

AN - SCOPUS:85009446471

VL - 67

SP - 93

EP - 99

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

SN - 0007-9235

IS - 2

ER -